| Scopolamine |
Transdermal |
Reciprocating disk (Apparatus 7) |
Stroke depth: 2-3 cm; 30-60 cycles per minute |
Distilled Water |
25 × 150 mm test-tubes containing 20 mL |
1, 2, 4, 6, 12, 18, 24, 36, 48, and 72 hours |
2009/07/15 |
| Secnidazole |
Granule |
I (Basket) |
50 |
Phosphate Buffer, pH 6.8 |
900 |
0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours |
2017/11/16 |
| Selegiline HCl |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Selegiline (20 mg/20 cm2 and 30 mg/30 cm2) |
Transdermal |
Paddle over Disk (Apparatus 5) |
50 |
0.1 M Phosphate buffer, monobasic, pH 5 at 32°C |
500 |
1, 2, 4, 8, 12, 16, 20 and 24 hours |
2009/07/15 |
| Selegiline (40 mg/40 cm2) |
Transdermal |
Rotating Cylinder (Apparatus 6) |
50 |
0.1 M Phosphate buffer, monobasic, pH 5 at 32°C |
1000 |
1, 2, 4, 8, 12, 16, 20 and 24 hours |
2009/07/15 |
| Selegiline HCl |
Tablet (Orally Disintegrating) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Selexipag |
Tablet |
II (Paddle) |
50 |
Phosphate Buffer, pH 6.8 |
900 |
5, 10, 15, 20 and 30 |
2016/03/17 |
| Selinexor |
Tablet |
II (Paddle) |
75 |
10 mM Citric Acid Buffer, pH 4.5 with 0.5% SDS |
900 |
10, 15, 20, 30 and 45 |
2021/08/19 |
| Selpercatinib |
Capsule |
II (Paddle) |
75 |
0.1N HCl |
900 |
5, 10, 15, 20 and 30 |
2022/07/07 |
| Selumetinib |
Capsule |
II (Paddle) with sinker |
75 |
Sodium Phosphate Buffer, pH 6.5, with 0.5% Polysorbate 80 |
1000 |
10, 20, 30, 45 and 60 |
2022/07/07 |
| Semaglutide |
Tablet |
II (Paddle) |
70 |
50 mM Phosphate Buffer with 0.05% Brij 35 (polyoxyethylene lauryl ether), pH 6.8 |
500 |
10, 15, 20, 30, 45, 60 and 75 |
2021/08/19 |
| Sertraline HCl |
Capsule |
II (Paddle) with sinker |
75 |
0.1 N HCl |
900 |
10, 15, 20, 30 and 45 |
2023/07/07 |
| Sertraline HCl |
Tablet |
II (Paddle) |
75 |
0.05 M Sodium Acetate Buffer, pH 4.5 |
900 |
10, 20, 30 and 45 |
2004/02/20 |
| Sevelamer Carbonate |
Tablet |
|
|
Disintegration Testing in 0.1 N HCl as per USP <701> |
|
|
2008/10/06 |
| Sevelamer HCl |
Capsule |
|
|
Disintegration Testing in 0.1 N HCl as per USP <701> |
|
|
2008/04/09 |
| Sevelamer HCl |
Tablet |
|
|
Disintegration Testing in 0.1 N HCl as per USP <701> |
|
|
2008/04/09 |
| Sibutramine HCl |
Capsule |
II (Paddle) |
50 |
0.05 M Acetate Buffer, pH 4.0 |
500 |
10, 20, 30, 45 and 60 |
2004/02/25 |
| Sildenafil Citrate |
Tablet |
I (Basket) |
100 |
0.01 N HCl |
900 |
5, 10, 15 and 30 |
2006/03/04 |
| Sildenafil Citrate |
Suspension |
II (Paddle) |
50 |
McIlvaine Buffer, pH 5.0 |
500 |
5, 10, 15, 20 and 30 |
2015/05/28 |
| Silodosin |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |